Ampligen® Has Significant Opportunity Across High-Value Multiple Disease Areas
~100,000 IV doses in humans, generally well-tolerated
Positive Phase 3 data generated in U.S. in treatment of ME/CFS.
Data from multiple in-vitro, preclinical (animal) models and clinical studies provide encouraging results in a range of potential clinical uses
Demonstrated safety and generally well tolerated across a number of clinical studies
Approved in Argentina for treatment of severe chronic fatigue syndrome
PD-1 and PD-L1 potential synergies with checkpoint inhibitors